Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: Efficacy, safety and feasibility-an open-label, 6-week study

Journal of Neural Transmission

Volumn 117, Issue 3, 2010, Pages 333-342

  Eggert, Karla ^a   Skogar, Örjan ^b   Amar, Khaled ^c   Luotonen, Lusa ^d   Kuoppamäki, Mikko ^d,e   Leinonen, Mika ^f   Nissinen, Helena ^d   Oertel, Wolfgang ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Lanssjukhuset Ryhov   (Sweden)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d ORION CORPORATION   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f 4Pharma ^*  (Sweden)

Author keywords

9 item wearing off questionnaire; Benserazide; Carbidopa; Entacapone; Levodopa; Wearing off

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COLD INJURY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FATIGUE; FEASIBILITY STUDY; FEMALE; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PACEMAKER FAILURE; PARKINSON DISEASE; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RHINOPHARYNGITIS; SIDE EFFECT; SKIN INFECTION; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; URINE COLOR; VERTIGO; VISUAL ANALOG SCALE; VOMITING;

AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; CARBIDOPA; CATECHOLS; DRUG TOXICITY; DYSKINESIAS; FEASIBILITY STUDIES; FEMALE; HUMANS; LEVODOPA; MALE; NITRILES; PARKINSON DISEASE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952430396     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0344-4     Document Type: Article

References (17)

1. Brooks DJ, Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74:1071-1079 (Pubitemid 36936383)
2. Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A, The TC-INIT Study Group (2005) Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo®(Levodopa/Carbidopa/Entacapone) and levodopa/DDCI given in combination with Comtess®®(Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 53:197-202 (Pubitemid 41404749)
3. de la Fuente-Fernandez R, Stoessl AJ (2004) The biochemical bases of the placebo effect. Sci Eng Ethics 10:143-150
4. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ (2004) Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 56:67-71 (Pubitemid 38844781)
5. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, MartinezMartin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schräg A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mo v Disord 23:2129-2170 (Pubitemid 46382671)
6. Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone-a review. J Neural Transm 1.11:1343-1363 (Pubitemid 39468395)
7. Koller W, Guamieri M, Hubble J, Rabinowicz AL, Silver D (2005) An open-label evaluation of the tolerability and safety of Stalevo®(carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. 1.12:221-230 (Pubitemid 40179116)
8. Kuoppamáki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four- or five-times daily. Eur J Clin Pharmacol 65:443-455
9. Linazasoro G, Kulisevsky J, Hernandez B (2008) Should levodopa dose be reduced when switched to stalevo? Eur J Neurol 15:257-261
10. Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006a) Pharmacokinetic behaviour of levodopa and 3-0-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural. Transm 113:1441-1448 (Pubitemid 44435882)
11. Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D (2006b) Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 21:332-336
12. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19:997-1005 (Pubitemid 39302831)
13. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42:747-755 (Pubitemid 27481547)
14. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurologica Scand 1.05:245-255 (Pubitemid 34407226)
15. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, The Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309-13.14 (Pubitemid 28520549)
16. Stacy M, Häuser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E (2006) End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 29:312-321 (Pubitemid 44729942)
17. Stocchi F (2006) The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 7:1399-1407